Full text
Earnings transcript
Read the complete earnings call transcript.
SGMO
Sangamo Therapeutics, Inc.
$0.07
0
(0%)
| Exchange: | OTC |
| Market Cap: | 30.657M |
| Shares Outstanding: | 5.143M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Alexander D. Macrae Ch.B | |||||
| Full Time Employees: | 127 | |||||
| Address: |
| |||||
| Website: | https://www.sangamo.com |
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. ALS and Frontotemporal Lobar Degeneration; Takeda Huntington’s Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 176,232 | 57,800 | 39,552 |
| Gross Profit | 176,232 | 57,800 | 31,950 |
| EBITDA | -96,800 | -89,087 | -115,898 |
| Operating Income | -274,005 | -103,969 | -108,004 |
| Net Income | -257,831 | -97,941 | -122,932 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 165,320 | 101,635 | 59,745 |
| Total Liabilities | 82,433 | 78,865 | 74,013 |
| Total Stockholders Equity | 82,887 | 22,770 | -14,268 |
| Total Debt | 38,104 | 30,566 | 25,093 |
| Cash and Cash Equivalents | 45,204 | 41,918 | 20,948 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -224,842 | -67,139 | -97,208 |
| Capital Expenditure | -21,155 | -267 | -102 |
| Free Cash Flow | -245,997 | -67,406 | -97,310 |
| Net Income | -257,831 | -97,941 | -122,932 |
| Net Change in Cash | -55,240 | -3,286 | -22,470 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 268,917.154 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 269,082.845 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 269,000 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | -244,826.423 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | -244,675.668 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | -244,751.046 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 36,411.080 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 36,439.099 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 36,425.090 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 168,729.325 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 168,833.287 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 168,781.306 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 0.130 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 0.130 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 0.130 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 1 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Innovative Pipeline in Gene Therapy: Sangamo Therapeutics demonstrates a strong focus on gene therapy and genomic medicine, as highlighted in the Q4 2024 earnings call summary. Their progress in clinical trials, particularly in areas like Fabry disease, positions them as a potential leader in niche therapeutic markets.
- Strategic Partnerships: The company is actively seeking partnerships for key programs, such as the Fabry trial, which could provide financial and operational support, reducing risk and enhancing development capabilities.
- Solid Cash Position: Based on balance sheet data, Sangamo maintains a level of cash and cash equivalents that supports ongoing R&D efforts, providing a buffer for operational needs in the short term.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about SGMO valuation
Is Sangamo Therapeutics, Inc. (SGMO) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Sangamo Therapeutics, Inc. (SGMO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is SGMO a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SGMO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is SGMO’s P/E ratio?
You can see SGMO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for SGMO?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is SGMO a good long-term investment?
Whether SGMO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
SGMO
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0
Trading Metrics:
| Open: | 0.13 | Previous Close: | 0.07 | |
| Day Low: | 0.06 | Day High: | 0.13 | |
| Year Low: | 0.06 | Year High: | 0.77 | |
| Price Avg 50: | 0.15 | Price Avg 200: | 0.37 | |
| Volume: | 28.503M | Average Volume: | 9.179M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeSGMO full analysis
Welcome to MARKETSNAP’s SWOT analysis for Sangamo Therapeutics, a biotech player that might not be on everyone’s radar but definitely deserves a closer look if you’re hunting for long-term opportunities in the healthcare space. I’m pumped to dive into this one with you today, breaking down the strengths, weaknesses, opportunities, and threats for this company, while also giving you the bigger picture on where they stand and what could drive their future. So, let’s get right into it! First off,…
